That is not apathy
In addition to diabetes and obesity, GLP-1 drugs have been widely applied in clinical trials in various diseases, including fatty liver disease, cardiovascular disease, Alzheimer's disease, Parkinson's disease, and chronic kidney disease
GLP-1 therapy is particularly considered in patients with a BMI 35 kg/m or those who would benefit from weight loss
Gao S, Xu B, Sun J, Zhang Z
These are not conclusions yet they are clues
However, if you frequently adjust your injection schedule in both directions (early one week, late the next), you may experience more unpredictable side effect timing as your body struggles to establish a consistent medication rhythm